• Lauri E Markowitz, Susan Hariri, Elizabeth R Unger, Mona Saraiya, S Deblina Datta, and Eileen F Dunne.
• Centers for Disease Control and Prevention, MS E05, 1600 Clifton Rd, Atlanta, GA 30333, USA. lem2@cdc.gov
• Vaccine. 2010 Jul 5; 28 (30): 4731-7.

AbstractPost-licensure evaluation of vaccines plays an important role in monitoring the progress of immunization programs, demonstrating population impact of vaccines, and providing data for ongoing policy decisions. Two human papillomovirus (HPV) vaccines are licensed and recommended for use in females in the United States, a quadrivalent human HPV vaccine, licensed in 2006 and a bivalent vaccine HPV vaccine licensed in 2009. HPV vaccination is recommended for females 11 or 12 years of age with catch-up vaccination through age 26 years. Post-licensure monitoring of the HPV vaccine program has included some of the same systems established for other vaccines, such as those for vaccine safety and coverage monitoring. However, monitoring HPV vaccine impact on infection and disease outcomes has required new efforts. While there are well established cancer registries in the United States, it will take decades before the impact of vaccine on cervical cancer is observed. More proximal measures of vaccine impact include outcomes such as prevalence of HPV vaccine types, incidence of cervical precancers and genital warts. We review systems in place or being established for post-licensure monitoring of HPV vaccine in the United States.Published by Elsevier Ltd.

23 keywords...

hide…